- Home
- ICCM vs VNRX Comparison
ICCM vs VNRX Comparison
Compare ICCM & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- VNRX
- Stock Information
- Founded
- ICCM 2006
- VNRX N/A
- Country
- ICCM Israel
- VNRX United States
- Employees
- ICCM N/A
- VNRX N/A
- Industry
- ICCM
- VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ICCM
- VNRX Health Care
- Exchange
- ICCM Nasdaq
- VNRX Nasdaq
- Market Cap
- ICCM 59.9M
- VNRX 52.4M
- IPO Year
- ICCM N/A
- VNRX N/A
- Fundamental
- Price
- ICCM $1.05
- VNRX $0.66
- Analyst Decision
- ICCM Strong Buy
- VNRX Strong Buy
- Analyst Count
- ICCM 1
- VNRX 5
- Target Price
- ICCM $2.50
- VNRX $3.88
- AVG Volume (30 Days)
- ICCM 361.2K
- VNRX 318.9K
- Earning Date
- ICCM 08-19-2025
- VNRX 08-13-2025
- Dividend Yield
- ICCM N/A
- VNRX N/A
- EPS Growth
- ICCM N/A
- VNRX N/A
- EPS
- ICCM N/A
- VNRX N/A
- Revenue
- ICCM $3,273,000.00
- VNRX $1,308,361.00
- Revenue This Year
- ICCM $83.41
- VNRX $563.72
- Revenue Next Year
- ICCM $185.02
- VNRX $160.43
- P/E Ratio
- ICCM N/A
- VNRX N/A
- Revenue Growth
- ICCM 0.34
- VNRX 64.16
- 52 Week Low
- ICCM $0.48
- VNRX $0.40
- 52 Week High
- ICCM $1.66
- VNRX $0.94
- Technical
- Relative Strength Index (RSI)
- ICCM 51.32
- VNRX 47.94
- Support Level
- ICCM $0.96
- VNRX $0.62
- Resistance Level
- ICCM $1.17
- VNRX $0.76
- Average True Range (ATR)
- ICCM 0.08
- VNRX 0.08
- MACD
- ICCM 0.01
- VNRX -0.02
- Stochastic Oscillator
- ICCM 63.89
- VNRX 12.47
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.